Viking Therapeutics Faces Investor Scrutiny Over Weight-Loss Drug Tolerability

Investors are reassessing Viking Therapeutics’ clinical trial data as concerns emerge about patient discontinuation rates in the study of oral obesity treatment VK2735. While the drug demonstrated impressive efficacy results, market attention has shifted toward its tolerability profile and potential commercial implications.

The study’s primary endpoint was clearly achieved with statistically significant weight reductions of up to 12.2% after 13 weeks of treatment. Researchers observed a clear dose-dependent response, indicating the compound’s potent biological activity. These effectiveness metrics would typically generate substantial investor enthusiasm in the competitive weight-loss pharmaceutical sector.

Tolerability Concerns Emerge

The trial revealed that approximately 20% of participants receiving VK2735 discontinued treatment due to adverse effects, compared to 13% in the placebo group. This seven-percentage-point difference has... Read more...